Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
42
Participants
Timeline
Start Date
October 31, 1995
Study Completion Date
June 30, 2000
Conditions
Breast NeoplasmsNeoplasm Metastasis
Interventions
GENETIC
peripheral blood progenitor cells carrying MDR1
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001493 - Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer | Biotech Hunter | Biotech Hunter